British pharmaceutical giant GSK (LSE:GSK) is expected to end Wednesday’s trading down about 3%. The London-based pharmaceutical company earlier announced its third quarter financial results and updated forecasts for the entire year 2024.
Overall sales fell 2% from the same period in 2023 to £8.01 billion ($10.41 billion), slightly above analysts’ expectations. GSK also beat Wall Street expectations, reporting core earnings per share of around £0.50, down 1% compared to the third quarter of last year.
The company kept its full-year sales and profit forecasts unchanged, but revised down its vaccine sales forecast for 2024 for the second time.
This article is accessible to registered users. Register for free to read more. Your free trial gives you one week of access to exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
Log into your account
TRY BEFORE YOU BUY
free
7-day trial access
Get a free trial All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analysis, and commentary from our global network of life science reporters. Receive The Pharma Letter’s daily news bulletins free forever.
become a subscriber
£820
or £77 per month
Subscribe Now Get free access to industry-leading news, commentary and analysis in Pharma & Biotechnology. Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legal, executive appointments, commercial strategy, and financial results. A daily roundup of important events in pharma and biotechnology. We hold monthly in-depth briefings on board appointments and M&A news. Choose from cost-effective annual packages or flexible monthly subscriptions. The Pharma Letter is a highly useful and valuable life sciences service that brings together daily updates on performance people and products. This is some important information to keep me informed
Chairman of Sanofi-Aventis UK
Sign up to receive email updates
Join industry leaders and get the daily round-up of biotech and pharma news
